Rhinitis and epistaxis in patients treated by anti-angiogenic therapy

V. Prulière-Escabasse, E. Escudier, R. Balheda, J. C. Soria, A. Coste, C. Massard

    Research output: Contribution to journalArticlepeer-review

    8 Citations (Scopus)

    Abstract

    Anti-angiogenic therapies have a particular drug-related toxicity profile including hypertension, thrombosis, haemorrhages, and proteinuria. Moreover, patients treated by angiogenesis inhibitors present nasal symptoms including symptomatic rhinitis and epistaxis. For the first time, a new entity of "atrophic rhinitis" induced by angiogenesis inhibitors is described and revealed that angiogenesis inhibitors alter the differentiation of nasal epithelium. VEGF may act on epithelial cell proliferation and differentiation in nasal epithelium.

    Original languageEnglish
    Pages (from-to)285-286
    Number of pages2
    JournalInvestigational New Drugs
    Volume27
    Issue number3
    DOIs
    Publication statusPublished - 1 Jun 2009

    Keywords

    • Angiogenic therapy
    • Epistaxis
    • Rhinitis
    • VEGF

    Cite this